Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (ACRX) on February 14, 2022, covering events occurring on February 9, 2022. The registrant is a Delaware corporation headquartered in Hayward, California, with common stock listed on the Nasdaq Global Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on executive compensation arrangements.
Material Changes
The primary material event reported is the approval by the Compensation Committee and Board of Directors of time-based stock options and restricted stock units (RSUs) for four named executive officers under the Amended and Restated 2020 Equity Incentive Plan. The grant date for these awards is February 11, 2022.
| Named Executive Officer | Time-Based Stock Options | Restricted Stock Units (RSUs) |
|---|---|---|
| Vincent J. Angotti (CEO) | 780,000 | 390,000 |
| Pamela Palmer, M.D., Ph.D. (CMO) | 245,000 | 122,500 |
| Raffi Asadorian (CFO) | 235,000 | 117,500 |
| Badri Dasu (Chief Engineering Officer) | 195,000 | 97,500 |
Guidance, Outlook, and Terms
The filing does not contain financial guidance, outlook, or management commentary on business performance. It details the vesting terms for the equity awards:
- Stock Options: One-fourth (1/4) vests on the one-year anniversary of the grant date; the remainder vests in equal monthly installments over the subsequent 36 months, subject to continuous service.
- RSUs: Vest in three equal consecutive annual installments on February 11, 2023, February 11, 2024, and February 11, 2025, subject to continuous service.
Full terms are governed by the Plan and specific grant agreements referenced in prior 10-Q filings.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2020 Equity Incentive Plan to assess remaining availability for future grants.
- Review the specific vesting acceleration clauses and termination provisions in the Plan (Exhibit 10.7 and 10.8 of the August 10, 2020 10-Q).
- Confirm the current share price and fair value assumptions used to calculate the expense impact of these grants on future financial statements.
- Check for any subsequent filings regarding the exercise of options or changes in executive tenure.